Sy Ha
YOU?
Author Swipe
View article: Iron overload and morbidities in Chinese with non‐transfusion‐dependent thalassaemia
Iron overload and morbidities in Chinese with non‐transfusion‐dependent thalassaemia Open
Summary Non‐transfusion‐dependent thalassaemia (NTDT) is associated with chronic health problems. A cross‐sectional study was conducted in Hong Kong Chinese patients to evaluate the presentation and complications of NTDT. One hundred and n…
View article: Dabrafenib in pediatric patients with <i>BRAF</i> V600 mutation–positive high-grade glioma: Results from a phase 1/2a single-arm study
Dabrafenib in pediatric patients with <i>BRAF</i> V600 mutation–positive high-grade glioma: Results from a phase 1/2a single-arm study Open
Background BRAF V600E mutations occur in many pediatric malignancies, including ~5% to 10% of pediatric high-grade gliomas (HGGs). Despite efforts over the decades, the prognosis of pediatric HGG remains dismal, with low survival rates. Da…
View article: DOP080 Artificial Intelligence-Based Prediction of Nancy Grade Activity Using Digital Pathology in Ulcerative Colitis Patients
DOP080 Artificial Intelligence-Based Prediction of Nancy Grade Activity Using Digital Pathology in Ulcerative Colitis Patients Open
Background Therapeutic goals of Ulcerative colitis have shifted from symptom control to achieving endoscopic and histologic remission as a key predictor of long-term outcomes. The Nancy Histological Index is widely used to assess histologi…
View article: CTNI-22. DABRAFENIB (D) AND TRAMETINIB (T) EITHER IN COMBINATION OR AS MONOTHERAPY IN PEDIATRIC PATIENTS HARBORING<i>BRAF</i> ALTERATIONS IN GLIOMAS OR OTHER RARE TUMORS: FINDINGS FROM AN EARLY ACCESS PROGRAM (EAP)
CTNI-22. DABRAFENIB (D) AND TRAMETINIB (T) EITHER IN COMBINATION OR AS MONOTHERAPY IN PEDIATRIC PATIENTS HARBORING<i>BRAF</i> ALTERATIONS IN GLIOMAS OR OTHER RARE TUMORS: FINDINGS FROM AN EARLY ACCESS PROGRAM (EAP) Open
BACKGROUND In 2022, dabrafenib and trametinib (D+T) combination received an accelerated US FDA approval for use in adult and pediatric patients with BRAF V600E–mutated unresectable or metastatic solid tumors with no viable alternative ther…
View article: Delivering participatory food systems research in our own communities: reflections about co-production by community food researchers and community partners
Delivering participatory food systems research in our own communities: reflections about co-production by community food researchers and community partners Open
This article offers insights into delivering community-engaged research (co-production), from the perspectives of engaged citizens and community partners. It adds to scholarship addressing epistemic justice issues that the experiences of e…
View article: Optimized cytogenetic risk-group stratification of <i>KMT2A</i>-rearranged pediatric acute myeloid leukemia
Optimized cytogenetic risk-group stratification of <i>KMT2A</i>-rearranged pediatric acute myeloid leukemia Open
A comprehensive international consensus on the cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Stu…
View article: Case report: Therapy-related myeloid neoplasms in three pediatric cases with medulloblastoma
Case report: Therapy-related myeloid neoplasms in three pediatric cases with medulloblastoma Open
Introduction Medulloblastoma is the most common malignant brain tumor in children, often requiring intensive multimodal therapy, including chemotherapy with alkylating agents. However, therapy-related complications, such as therapy-related…
View article: Acute megakaryoblastic leukemia mimicking a disseminated tumor
Acute megakaryoblastic leukemia mimicking a disseminated tumor Open
Acute megakaryoblastic leukaemia is an uncommon form of paediatric cancer. Extramedullary leukaemia in acute megakaryoblastic leukaemia is rare, which is reported to be associated with increased risk of induction death. This atypical prese…
View article: Supplementary Data from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
Supplementary Data from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine Open
Supplementary Data from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
View article: Supplementary Figure from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
Supplementary Figure from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine Open
Supplementary Figure from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
View article: Supplementary Figure from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
Supplementary Figure from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine Open
Supplementary Figure from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
View article: Data from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
Data from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine Open
Despite the expanding portfolio of targeted therapies for adults with acute myeloid leukemia (AML), direct implementation in children is challenging due to inherent differences in underlying genetics. Here we established the pharmacologic …
View article: Supplementary Data from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
Supplementary Data from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine Open
Supplementary Data from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
View article: Data from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
Data from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine Open
Despite the expanding portfolio of targeted therapies for adults with acute myeloid leukemia (AML), direct implementation in children is challenging due to inherent differences in underlying genetics. Here we established the pharmacologic …
View article: The incidence, risk factors, and outcomes of symptomatic avascular necrosis of bone among Chinese pediatric patients with acute lymphoblastic leukemia
The incidence, risk factors, and outcomes of symptomatic avascular necrosis of bone among Chinese pediatric patients with acute lymphoblastic leukemia Open
Background Avascular necrosis (AVN) of bone is a debilitating complication of pediatric patients with acute lymphoblastic leukemia (ALL). While it is extensively studied and reported in Western population, studies focused on Orientals are …
View article: Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group Open
PURPOSE A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood KMT2A-rearranged ( KMT2A-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value …
View article: Dabrafenib, alone or in combination with trametinib, in <i>BRAF</i> V600–mutated pediatric Langerhans cell histiocytosis
Dabrafenib, alone or in combination with trametinib, in <i>BRAF</i> V600–mutated pediatric Langerhans cell histiocytosis Open
Langerhans cell histiocytosis (LCH) is a rare, heterogenous, neoplastic disorder primarily affecting children. BRAF mutations have been reported in >50% of patients with LCH. The selective BRAF inhibitor, dabrafenib, in combination with…
View article: Neutropenia and anaemia secondary to copper deficiency in a child receiving long-term jejunal feeding: a case report
Neutropenia and anaemia secondary to copper deficiency in a child receiving long-term jejunal feeding: a case report Open
In January 2017, a girl was born full term to nonconsanguineous Chinese parents.Oesophageal atresia with a distal tracheo-oesophageal fistula was diagnosed soon after birth.Emergency surgical repair was attempted on day 1 of life but was c…
View article: EVALUATING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH YOUNG-ONSET TYPE 2 DIABETES IN SINGAPORE USING EuroQol EQ-5D-5L
EVALUATING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH YOUNG-ONSET TYPE 2 DIABETES IN SINGAPORE USING EuroQol EQ-5D-5L Open
OBJECTIVESDespite multiple efforts to create awareness and reduce the rise of young-onset T2D (YT2D), the prevalence of YT2D remains high in Singapore. There is also limited information on how YT2D patients have been coping with their chro…
View article: Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension
Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension Open
Objective To investigate the long-term efficacy and tolerability of osilodrostat, a potent oral 11β-hydroxylase inhibitor, for treating Cushing's disease (CD). Design/methods A total of 137 adults with CD and mean 24-h urinary free cortiso…
View article: Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine Open
Despite the expanding portfolio of targeted therapies for adults with acute myeloid leukemia (AML), direct implementation in children is challenging due to inherent differences in underlying genetics. Here we established the pharmacologic …
View article: Outcomes of adolescents with acute lymphoblastic leukaemia
Outcomes of adolescents with acute lymphoblastic leukaemia Open
Adolescents with ALL had worse survival because they experienced a greater incidence of TRD. There is a need to investigate optimal treatment adjustments and novel targeted agents to achieve better survival rates (without excessive toxicit…
View article: Successful haploidentical hematopoietic stem cell transplantation (HSCT) and durable engraftment by repeated donor lymphocyte infusions for a Chinese patient with transfusion‐dependent hemoglobin (Hb) Hammersmith and massive splenomegaly
Successful haploidentical hematopoietic stem cell transplantation (HSCT) and durable engraftment by repeated donor lymphocyte infusions for a Chinese patient with transfusion‐dependent hemoglobin (Hb) Hammersmith and massive splenomegaly Open
Background Hemoglobin (Hb) Hammersmith is a rare form of unstable β‐chain hemoglobinopathy causing hemolytic anemia. This rare event led to a more serious transfusion‐dependent phenotype in a patient. It was successfully cured by haploiden…
View article: Randomized Trial of Osilodrostat for the Treatment of Cushing Disease
Randomized Trial of Osilodrostat for the Treatment of Cushing Disease Open
Context Cushing disease, a chronic hypercortisolism disorder, is associated with considerable morbidity and mortality. Normalizing cortisol production is the primary treatment goal. Objective We aimed to evaluate the safety and efficacy of…
View article: Clinical outcomes of second relapsed and refractory first relapsed paediatric <scp>AML</scp>: A retrospective study within the <scp>NOPHO‐DB SHIP</scp> consortium
Clinical outcomes of second relapsed and refractory first relapsed paediatric <span>AML</span>: A retrospective study within the <span>NOPHO‐DB SHIP</span> consortium Open
Summary As treatments for second relapsed and refractory first relapsed paediatric AML transition from purely palliative to more commonly curative in nature, comparative data is necessary for evaluating the effectiveness of emerging treatm…